

Polygenic Risk Scoring and Treatment Response Prediction: Advances in Machine Learning Models for Precision Personalised Medicine

Dr. Sudarshan Bhattacharyya, Professor of Computer Science, Indian Institute of Technology Kharagpur (IIT Kharagpur)

1. Introduction to Personalized Medicine

Personalized approaches are becoming pivotal for modern health care. For many years, standard clinical protocols would assume that every patient with the same symptoms should receive the same type of treatment. However, everyone can have different genotypes, backgrounds, symptoms, and various treatment histories. Therefore, personalized medicine suggests that treatment be customized for the individual characteristics of each patient. Advantages of personalized medicine include reduced side effects, improved patient outcomes, patient-specific therapy, and reduced trial-and-error behavior. It is also shifting the focus of medical research from treatments of diseases at the population level to individuals. Due to personalized medicine and targeted therapies, personalized AI-developed models can be created and evaluated for each patient. Recent advancements in technology and the accumulation of data have made this possible: AI and genomic medicine have delivered results that are changing clinical practice and the standard of care in the clinic for some diseases.

The systematic development of population-based genomic medicine and pharmacogenomics relies on the significant reduction in cost and the quantity of time required to determine a patient's whole genomic profile. In the near future, genomic technologies will allow us to determine each person's composition and dig into their potential future health risks. Also, advances in technology, including genomics, oxidative typing, metabolomics, and microbiome studies, can develop a technology known as Petri dish narratives based on results from these technologies. The paper will give an overview of the clinical applications of personalized machine learning.

1.1. Definition and Importance

A new paradigm in the healthcare field has been ushered in by a systems-oriented approach which, through the use of emerging technologies, aims to understand the molecular and clinical traits that, even at the earliest stages of disease, distinguish each individual patient. In the mid-20th century, studies on inherited individuals' genetic variability through genome-wide association studies and loss-of-function mutations helped pioneer the era of personalized medical treatments tailored on the basis of an individual's genetic profile. Integrating a person's genetic, clinical, environmental, and lifestyle traits leads to a more accurate and complete understanding and treatment of healthcare conditions. Patient-tailored medicine, commonly known as personalized medicine, has been defined as "the use of new methods of molecular analysis to better manage a patient's disease or predisposition toward disease" and also as "the performance of two or more diagnostic tests obtaining information on patients' genetic constitution in order to decide on the optimal pharmacotherapeutical treatment for this individual."

Over the years, the definition of personalized medicine has evolved thanks to the accumulation of new knowledge and the advent of new paradigms in clinical practice and scientific research. Personalized medicine was the descriptive term for a strategy that sought to identify responder patients eligible for a targeted therapy by screening for a disease-related genetic trait. Presently, the understanding of the conundrum posed by cardiovascular diseases, diabetes, and cancer converges into the development of concepts like "precision medicine," which is close in meaning to personalized medicine, but does not confine itself to a focus on the genome, given the avant-garde cutting edge of other "-omics" and "multi-omics" fields like metabolomics, proteomics, glycoprofiling, and multi-omics integration. Technologies such as genomics, next-generation sequencing, or proteomics combinatorically coupled with novel algorithms of computational biology and bioinformatics give us the potential to generate a tremendous amount of data consisting of millions of molecular profiles for each individual patient. Given the opportunities and challenges of big data in healthcare, new technological and machine learning models require the simultaneous involvement of different types of features referring to different areas of medical, scientific, and technological knowledge. On the one hand, innovative genomics information systems are revolutionizing a hospital information system that is called into question by the

advent of personalized medicine. The bottom-up redesign passes first and foremost through interfaces with genomics information systems and computational biology tools, alongside a radiomics revolution. The importance of the above-mentioned convergences leads to a new design for the hospital system and population health: a new cardiologist figure named the “physician-data scientist” is necessary. Key citizens and patients are active in their co-production of health and are more committed to health and welfare in the search for meaning, to improve lifestyles, to acquire well-being, and also to extend longevity with a better life and higher quality of life. Pre-symptomatic individuals who habitually measure tens of biological parameters such as blood pressure, continuous glucose monitoring, lipid profile, and wearables in the era of quantified self are ushering in ‘wellness 5.0’ following wellness 4.0 and genetic biobanks. The ambitious goal is to measure as many as possible of the 20,000 features that describe an individual’s biological and physical functions via -omics – in particular glycomics, proteomics, or micro-RNomics indicative of inflammation – a source of aging and senescence. Capturing this complexity will end with a significant grant to closely map the cancer genome.

1.2. Historical Development

Personalized medicine is fundamentally changing the paradigm of healthcare by offering tailored treatments for any given patient, overcoming the traditional one-size-fits-all approach. The history of medicine has primarily adopted a generalized approach, disregarding rare, atypical conditions in biomarker pathways. The foundational Human Genome Project defined acquired deoxyribonucleic acid (DNA) sequences, comprising approximately 3.2 billion nucleotides. Thereafter, genetics and other new branches of biotechnology have been deployed in clinical pathology, particularly in oncology. Pharmacies realized that every human is different and, at the same time, their genetic makeup differs as well. Officials, oncologists, and pharmaceutical companies supported these new advancements in the post-genomic world. However, in the last decade, the role of “multi-omics” in personalized cancer therapy has seen multiple successes.

Present clinical cases have numerous theoretical practicalities that demonstrate the substantial burden of economically viable anti-cancer therapeutic molecules already recognized under the sensitive pathways evaluation of the “omic” spectrum. There could be a possibility that if the patient is at a primitive stage, biosystems may help them only

to understand the physiochemical nature of the disease; if so, then drug or other-assisted therapy should be "omics" guided or better tailored, and theragnostics should be formulated concomitantly. Targeted therapies are becoming increasingly popular these days in managing rare diseases through small toxic molecules, monoclonal antibodies, potential receptors, immunotherapy, and enzyme inhibitors, which have already validated the long-awaited dreams of a molecular pathologist and psychiatrist in a multi-disciplinary oncodiatic center.

2. Role of AI in Personalized Medicine

An AI subfield, machine learning, has brought forth a powerful set of statistical strategies that can be used for analyzing large amounts of healthcare data. Importantly, machine learning is prediction-oriented, designed to identify patterns and make correlations in extremely large datasets, the types of data generated in the study of medicine. When used in combination with human subject-specific data, machine learning can make predictions about customized health outcomes. There is now the promise of developing machine learning models to better understand an individual's biophysical state and how it responds to various environmental challenges. By analyzing this data, a machine learning model could link extensive measures with an individual's biology and better predict outcomes at the individual level.

Machine learning is now transforming three different areas of medicine: (1) increasing the accuracy through which patients can be objectively diagnosed with a specific disease; (2) increasing the accuracy in which the provider can objectively identify the most efficacious therapy for an individual's condition; (3) monitoring individuals' responses to therapy. Importantly, with the power to analyze extensive datasets, machine learning and other AI tools also have the ability to integrate omics data. Such work can help to foster collaborative efforts through data sharing and iterative learning, providing a set of ad-hoc analytics that can foster data sharing and comparison for global genomic efforts. Delivering real-time analytics, driven by machine learning, based on a patient's health status is also transforming clinical decision-making. By using an individual's historical data in combination with the global health outcomes data combined in a dataset, the input could guide the clinician in being able to translate health data on an individual level.

2.1. Overview of Machine Learning

Machine learning is a subfield of artificial intelligence and is essentially the study of algorithms that allow an AI system to learn from incoming data. In machine learning, data is often called features, independent variables, and predictors, while the output is what we are trying to predict or analyze. Machine learning algorithms are often categorized into three types, namely supervised learning, unsupervised learning, and reinforcement learning. In supervised learning, algorithms learn from labeled training data, and the goal is to make predictions for the new data that comes in. In unsupervised learning, the datasets are unlabeled, and the objective is finding the hidden structure in the data. In reinforcement learning, an agent observes the environment, determines and executes the actions to perform, and receives a reward, which is the consequence of these decisions. Machine learning models are trained under a combination of features like algorithms, the domain, and type of data. Broadly, the performance of these models—how accurate they are in making a decision or prediction—depends on the quality and quantity.

Machine learning has increased the precision and performance of predictive analytics. Applications of machine learning in personalized medicine improve the effectiveness of consultations and thus the quality of health and clinical outcomes in virtually all areas of medical practice. All health care organizations need to align themselves with evidence-based medicine with the clinician-patient interface and apply knowledge resources. Indeed, sophisticated algorithms identifying how clinical decisions are made from evidence accumulated from studies of patients can significantly impact the flow of personal health care via respondents and physicians at all stages of a health maintenance or disease management pathway. Personalized care is increasingly sought. In just one well-evidenced example, tailored drug dose regimes, not only based on trials of drug regimens in various populations, mainly defined as white Caucasian males, but also for specialty groups at risk of under- and over-doses, such as cystic fibrosis, are prognostically and clinically beneficial. As such, they have become the current state-of-the-art.

Machine learning allows models to be developed to potentially become part of the clinical decision-making process. Integration into the medical workflow is important, and machine learning algorithms must therefore not only be accurate and efficient but

also clinically interpretable, to allow these models to be part of clinical decision support systems.

2.2. Applications in Healthcare

In the healthcare sector, AI and machine learning have been instrumental in furthering the advancements of precision medicine to fit individual patient needs. AI and machine learning have been used to find insights from omics and biological data that can lead to a better classification of clinical presentations or a categorization of patients according to prognostic characteristics. Besides being helpful in personalizing treatments, machine learning is also being used to offer personalized risk assessments, clinical diagnostics, differential drug reactions and toxicities, as well as offer solutions for the optimization of patient management and standard clinical treatments. Reporting on AI and machine learning use in healthcare was limited to three main areas: genomics and other omics data, imaging, and electronic health records. AI and machine learning have found applications in genomics and other omics in the development and use of novel diagnostic assays, as well as in selecting computed tomography images for analysis. Tumors have been detected before they would, in standard clinical practice, in case studies using parallel multi-AI modalities. Other case studies also demonstrated successful integration of AI solutions in electronic healthcare records for chronic diseases or for optimizing the type and volume of a specific treatment. Indeed, AI and machine learning use in advanced medical imaging, such as MRI and CT scans, had a huge presence in the literature due to their heavy use in clinical settings.

Case studies in the use of AI and machine learning in healthcare were able to prove successful utilization with improvements seen across a diverse list of metrics primarily in clinical effectiveness. In the cancer space, levels of improvement from integrating AI and machine learning spanned from the early identification of major conditions to the personalization of patient treatment regimens in order to maximize outcomes and minimize side effects. AI and machine learning have shown successful utilization to aid in the early detection of cancer, or as an aid in multi-modal diagnostic classification. Furthermore, the use of AI and machine learning has also been unilaterally cited as being successful in offering improved treatment solutions around direct-to-consumer genomics in the pediatric cancer context. Precision treatment involves providing patients with a treatment selected based on their specific clinical, biological, molecular,

and genetic characteristics, as well as personal and lifestyle characteristics. However, precision treatment might not always be effective; researchers hope that by continuing to integrate research methods with omics datasets, additional features can be registered, and accurate predictions can be made for how a patient will respond to a specific treatment. Borrowing from oncology treatment, one could imagine a personalized research guide for physicians in this setting, where patients are assigned to a clinical trial with the highest marginal benefit of treatment and also the greatest expected overall response for that patient. Although the automation of precision treatment is cost-cutting and may increase the efficiency of healthcare delivery, there has been some resistance to introducing AI and machine learning-based healthcare solutions. This might be linked to fear of automation and the replacement of human labor, as has been seen in the industrial sector. However, most champions of personalized or precision medicine would suggest the use of machine learning must occur to provide the healthcare ideal, with the highest level of standard of care for a single patient. It can, and theoretically will, assist in labor, cost, and time-intensive functions, as well as optimize treatment pathways into the future. Evolving from the more general domain of artificial intelligence is the use of AI models based on machine learning and deep learning to personalize treatment pathways.

3. Utilizing AI for Tailoring Treatment Plans

Modern medicine and research have been influenced by multiple 'big data' advances. One avenue to truly individualize a patient's medical estimates and treatment options would be to more fully combine clinical and genetic data for a particular patient into one global measure, and then develop a tailored treatment option. Some industries have moved in the direction of leveraging AI to create and interpret a rich, combined picture of the patient, formed from several distinct and complementary data sources. These approaches call these databases 'patient experience' or 'patient journeys,' but in essence, they are providing data-driven profiles of patients. Our field has attempted to generate comprehensive profiles of patients from smaller data sources such as clinical and genetic data. This can be done in an unsupervised manner through methods such as purely cluster models or uncovered regression models.

One of the key challenges in combining genetic with clinical data, especially in randomized clinical trials, is the quantity of data available. In some trials, only

summary, rather than individual-level, genetic marker data is available. Where detailed data are available, AIs also require that genetic and clinical data occupy a similar space in the particular dimensions being exploited. This can be a challenge due to the COX issue unless phenotypes are targeted. Other limitations of some AIs include that they can be data-intensive, require large numbers of patients to generate usable profiles, and perform less well in very rare diseases. One of the final challenges is that many clinicians find it hard to implement AI without understanding the rationale behind its ultimate recommendations. It, therefore, can be important to utilize the outputs of sophisticated models in a way that can be easily verified by clinical teams. Despite these challenges, AIs offer a tantalizing opportunity to greatly refine and individualize treatment plans to promote adherence. If patients believe in a given treatment option, they may be more likely to adhere to suggested protocols once real, typical compliance and resistance patterns are observed.

AIs are now able to develop exceedingly tailored patient pathways in various clinical scenarios. For example, one AI was able to extract profiles of patients utilizing their disease experience as recorded in free-text electronic health records. Real-world evidence for the success of such personalized recommendation strategies is typified by the targeting of novel treatment pathways that heavily leverage patient guidance. This offers the exciting possibility of using AI in the discovery of novel clinical pathways that optimize the disease outcome. Similarly, AIs developed to help select between personalized exercise plans are able to categorize patients into resistance or sustained weight management.

3.1. Integration of Genetic and Clinical Data

Introduction The availability of clinical information, such as phenotypes, has long driven clinical decisions. Classically, approaches to personalized healthcare have relied on traditional clinical data to decentralize treatment to patient-specific variables. However, today, personalized medicine is described as the use of genetic or other molecular analysis to customize medical treatment. In light of this new paradigm, it is important to underline the complementary nature between classical clinical data and the new genetics and biology era. Most importantly, the combination of both types of data could lead to providing better care and treatment in complex diseases, whose clinical presentation cannot be explained entirely by classic genetic factors. Phenome-human

associations and Endo/Phenome-human associations may lead to a deeper understanding of why diseases are heterogeneous and could help to better identify patient subtypes. The inherent challenge of personalized medicine is the enormous heterogeneity found within complex diseases. Determining which patients are more likely to benefit from a given treatment is valuable. Integrating other omics data, other than some widely used HLA alleles, could enhance patient stratification. However, while bioinformatics and biostatistical tools are making fast advances in the reanalysis and interpretation of such genetic and molecular profiles, one striking observation so far is that an extensive integration of genetic or molecular data with phenome-human data and endo/phenome-human data is clearly underrepresented. One possible explanation for this is the necessity to standardize information using different controlled vocabularies or ontology-driven approaches to guarantee data exchange and interoperability between different stakeholders. Since, as we already know, the semantic framework cannot be used directly on the information extraction resources, socio-economic background may hinder the establishment of big costly longitudinal biobank investments. The development of harmonization frameworks to share or integrate phenome and endo/phenome with molecular biology should be implemented in collaborative approaches. A promising structure suggested to facilitate data integration is to establish cloud-based rather than centralized projects in a data sharing platform.

3.2. Challenges and Limitations

This white paper on AI and personalization in healthcare is supervised by scientists and experts in AI research. To personalize treatment plans in an increasingly efficient and precise way is the aim of personalized medicine. Artificial intelligence (AI) increasingly contributes to distinguishing features of the human body that are informative with regard to the expected patients' disease trajectory. There are a wide range of operational and scientific challenges associated with enabling this sector through AI.

This part discusses the challenges and limitations associated with using AI for personalizing treatment plans. One pertinent concern is about data use in this context, covering data privacy, data usage, and consent. Moreover, the ethical aspects related to the use of generated data also constitute an important set of limitations. The existence of biases in algorithms has a direct impact on the treatment recommended. It is thus crucial to work on developing equitable AI solutions. Data quality is another important

limitation. Data generation bias might affect the recommendations and results of AI models. The AI models need nearly perfect data, and the quality of input data is critical. Other practical challenges pertain to clinicians and healthcare workers to accept and trust AI-driven approaches. Regulatory challenges arise from the use of AI in medicine. Ongoing research is required to build a consensus around these problems and overcome these limitations. A balanced perspective between promoting AI and acknowledging its challenges and limitations is desired.

4. Case Studies and Success Stories

Real-world case studies demonstrating the power of modern AI for personalized or precision medicine are now starting to appear in the literature. A kidney transplantation case study illustrates how an AI-driven strategy successfully identified good clinical outcomes. In a population of epilepsy patients, it was shown that AI was able to identify individual non-adherence to medication trends up to two years in advance of clinical failure using long-term surveillance of variance in clinical and multimodal data streams, including patient-generated data.

Raw chest X-rays and free-text radiological reports were used to identify which patients admitted to hospital emergency departments would ultimately be hospitalized, regardless of the reason for admission. Another study looked at electrocardiograms and used machine learning to determine which of 53 different chronic diseases patients suffer from. These are only some of the leading examples of the use of AI in ingenious ways contributing significantly to specific areas of clinical practice and to wider healthcare delivery. They build plausible grounds for advocacy for investment in AI to be scaled up. These, and many more concrete successes in practical clinical decision support, show radiology and diagnostics making significant strides toward precision medicine. Recently, there is a growing number of case studies. Some recent, publicly available, and not previously shown at conferences are highlighted here. These include single-modality, multimodal, and heterogeneous data, single outcomes, and multiple outcomes, as well as both qualitative and quantitative measures.

These case studies, alongside the many others being published, include successful development and testing of individualized treatment predictions designed for clinical use. Additionally, the importance of high-quality data, extensive data refinement and preprocessing, feature selection, and computation is often discussed. This suggests

commonalities from which useful lessons can be learned. Key issues that have arisen include the need to develop modeling approaches that are robust to data quality and quantity effects, ethical and legal issues, and evaluation frameworks. Overall, this section is designed to provide relevant success stories illustrating how real-world AI advances can help clinical decision-making in personalized therapy options.

4.1. Real-world Applications

So, can AI solve the three main problems of personalized medicine: choosing between different treatments, or selecting the right dose or timing? One way to answer this question is by dipping one's toes in the water of several real-world applications of personalized medicine powered by AI. In 2020, a comprehensive overview of such successful real-world applications was proposed. While covering personalized healthcare more broadly, many applications target patient groups with varying demographics. For instance, individualized, model-predictive, and integral-dose concepts are applied to blood coagulation therapy in critically ill infants, children, and adolescents.

Other applications successfully target central cancer samples, populations with diabetes, or people of more advanced age. In oncology, personalized or stratified medicine has already proven its added benefit with therapies that target only a subpopulation where a genetic test predicts the treatment's efficacy. A closer look at biomarker-based treatment in epilepsy, and in the case of ketogenic diet management, investigates patient-specific variables to predict an optimal therapeutic effect. In personalized diabetes management, a closed-loop algorithm incorporates predictive analytics to reduce the future occurrence of nocturnal hypoglycemia events in clinical trials of both youth and adults with T1D.

Such applications mainly guarantee an improvement in clinical outcomes, for instance by reducing disease or by reducing the burden of side effects of treatment. A significant number of applications show improvements in safety, diminishing often fatal complications and slowing the rate of disease progression. For a smaller list of applications, the advantages range from an economic standpoint, where the cost of care, drug, or drug development is greatly affected by personalized healthcare, to the diagnostic or disease characterization and prognosis of patients. These applications address a wide range of health conditions, from general acute and chronic diseases such as cardio-metabolic diseases and neurodegeneration to more specific diseases such as

hemophilia, hypercholesterolemia, primary hyperoxaluria, and many types of cancer, from solid to liquid tumors. Considering the use of these applications as a litmus test for efficacy, it is important to note that they are all implemented in close interaction and strong collaboration between highly interdisciplinary research and care teams within a single hospital, group of hospitals, or research institute. With such applications, it is crucial to continuously collect, monitor, and improve the AI methods and routinely adjust the results for performance and efficacy. Although each domain has different concepts and characteristics, application development has also led to some shared challenges and solutions across AI-for-health systems.

4.2. Impact on Patient Outcomes

The evidence of AI-driven stratification and treatment pathways in personalized medicine leading to measurable and better outcomes is directly available for patients and certified by the Patient Reported Outcome Measures. There is direct and high-quality evidence that matching treatment to patients, or personalizing treatment or tailoring care pathways, involves patients. The number of these studies is increasing, particularly in the field of cancer with the increasing development of precision medicine treatments, and the focus of such studies has steadily moved from adherence and drug exposure analyses in Phase 2 studies to large randomized trials in treatment pathways, with and without the relevant targeted treatment.

Survival and other measures of patient outcomes. There is strong evidence that the further a treatment is personalized and matched to the patient, the greater the increase in patient-reported outcomes and, importantly, when personalized with multidimensional algorithms, patient engagement; equality and quality of life. Our strategies in personalized medicine have so far resulted in quality of life levels and well-being scores that are either similar to or better, on average, than the reference population. These observational randomized control trials overall show modest p-value and a 7 to 8-point difference in health-related quality of life and symptoms between the control and the experimental arms. In a separate study that developed a personalized, computer-driven treatment pathway algorithm for brain tumor patients, it was shown that overall survival increased by 160%, and 'healthy' survival, with important activities of daily living, increased by 281% compared to standard treatment with three-quarters the cost.

5. Future Directions and Ethical Considerations

There is no doubt that public interest in personalized medicine will continue to grow. Novel technologies will enhance the data available for predictive analytics. As complete genome sequencing becomes more widespread and less expensive, we can expect the development of more comprehensive polygenic risk scores that may also benefit therapeutic guidance. Machine learning has also made advances in learning from patient data to discover structures and patterns imperceptible to the analyst. A more personalized approach for predicting long-term medical events such as hospitalization or death can be envisioned. Data from wearable technology that continuously monitors people will become integrated with health records for a more patient-centered healthcare approach.

The future seems positive for a data-driven healthcare landscape. Driven by publicly available data and scientific competition, machine learning models will continue to improve. In time, they will likely approach expert-level diagnostics. However, barriers beyond technological development will continue to be a concern for personalized medicine. The ethical use of data will be paramount as models are only as robust and generalizable as the data from which they are assembled. The potential for systematically biasing an algorithm further underlines the need for stakeholder engagement and drafting strong ethical guidelines to ensure algorithm structure and decision-making are transparent and just. There will also likely be a disparity in who will benefit most from expensive personalized medical treatments. Access needs to be further democratized to ensure that healthcare can be fair and equitable. Building an integrated personalized medicine infrastructure that is transparent, participatory, and people-centered is the first general opinion on the topic.

5.1. Emerging Technologies

Advances in genetics and genomics, along with the development of next-generation sequencing, have had significant implications for tailoring medical treatments to optimize patient outcomes. Along with big data and artificial intelligence, healthcare has transformed into a new focus on individual needs rather than a one-size-fits-all approach. Cancer treatment, in particular, has advanced radiographically with the adoption of technologies such as positron emission tomography and magnetic resonance imaging. Personalized medicine will see a rise in clinical diagnostics and new models for

patient engagement. Variation in therapy will come from application to application; a physician will use a different system for therapy if a patient has been found to have liver failure or heart failure, depending on mutations detected, for example. This focus will be an important part of future research strategies. In the review that follows, we explore the new diagnostics that will be available through certain technological innovations as the next step in the clinical validation of personalized medicines.

The above listing provides an example of big data and advanced data mining in the clinical setting, providing genomics and proteomics, and a view of some of the new diagnostics and personalized medicine-themed informatics and diagnostic tools that are now shifting the interface in the cancer field. An analytical regulator measures the gene activity pattern associated with cancer and healthy disease-related cells. It examines the quantified gene activity profile of a relevant set of hypoxemia and rhEpo-induced gene regulators in patients treated with EPO. This technology is used to select applications to diagnose and monitor the response to cancer and predict patient-specific outcomes and treatment response.

5.2. Privacy and Data Security

Personalized medicine often makes use of data to adapt clinical treatments to an individual patient. Health data are sensitive by design, and patients trust that the data they generate will be kept private by physicians and other medical staff. While data are sometimes made available for research, such sharing typically occurs after data have been stripped of identifying information. Thus, treating a patient using a personalized method must consider how to balance the value that might be gained in sharing data against the increased risk of privacy breach.

At present, we lack a fundamental understanding of what brain data are actually private, and even what 'private' might mean in a data disclosure context. The term 'private' in traditional data privacy is interpreted to mean that an external data user gains no information beyond that provided in a data statement. This situation is different in a healthcare context; a data user may in fact gain additional information by combining released data with other knowledge held by the individual. Protecting patient data from unauthorized use or distribution is always important, and information leaks resulting from data breaches or sharing different kinds of information can be utilized and combined by adversaries to provide a more comprehensive view of privacy.

There are different levels of challenges associated with cybersecurity in the healthcare sector. A variety of classes of attackers related to unauthorized access and the theft, misuse, and exploitation of sensitive data, including health information, could target healthcare organizations. Many current and proposed therapies in personalized medicine target diseases that can have a stigma and can prejudice the opinion of a patient's future health and insurability. For that reason, it is crucial to ensure data security, and privacy can be protected when it comes to developing and adhering to healthcare standards or regulatory requirements. Because it is increasingly hard to fairly portray adverse events and privacy risks relevant to big data to an average data contributor/patient, new protection pathways are being explored. For example, lengthier and more carefully elaborated consent documentation may be considered. Such pathways overcome several obvious informational deficiencies, but they may have the side effect of undermining patient autonomy. We also have a duty to determine whether it is just as important that consent-based ethics for data sharing at large and broad-scale in-clinic and near-clinical trials evolve with the science and data-prognostic advances in the clinic, and whether the potential benefits of such a societal dialogue as personalized decisions improve will outweigh its costs.

6. Conclusion

In sum, the development and application of machine learning models are revolutionizing healthcare. The integration of AI technologies, alongside systematic and curative processes, is critical in order to provide patients with individualized strategies and avoid malpractice. Personalized medicine will enrich management and treatment plans, but also diagnosis, prevention, and therapeutics, and in turn reduce adverse effects and improve the quality of life of those who undergo these programs. With the increasing emergence of personalized medicine in medical care, many biomedical stakeholders and researchers are working together to produce cutting-edge research in AI and other healthcare technologies that will ultimately improve patient care.

Several obstacles, nevertheless, must be overcome in order to actualize better healthcare technologies. The advancement of these systems needs further research investment and multidisciplinary research efforts that span specialty areas such as AI, clinical knowledge, and prevention. Lastly, the creation and use of smart personalized clinical decision aids must preserve patient-centered treatment approaches. In conclusion, a

fundamental requirement for better clinical results is the application of machine learning models in personalized medicine, which possibly enhances treatment and healthcare.